PMHS supply chain intelligence for Polomar Health Services, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Polomar Health Services, Inc. (PMHS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IG4 | IG4 | 90% | IG4 provides account management services on behalf of the Company |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| FORHUMANITY | FORHUMANITY | 92% | The Company has granted ForHumanity exclusivity to market products to potential customers through June 30, 2026, in exchange for the $750,000 guaranteed payment |
| MARKETING-PARTNERS | MARKETING-PARTNERS | 90% | The increase in revenues over the previous accounting period was primarily due to the contractual obligations of the registrant's marketing partners and customers, due to an increase in fulfillment o… |
| FORHUMANITY-HEALTH-INC | FORHUMANITY-HEALTH-INC | 85% | Company to show the applied for mark being used in commerce, and to amend its description of goods. On October 24, 2025, the Company filed a response with the USPTO amending its description of goods … |
| COMPANY-POLOMAR-MERGER-SUB-INC | COMPANY-POLOMAR-MERGER-SUB-INC | 62% | allows ForHumanity to exclusively market (through April 30, 2026), Polomar’s previously licensed, patent pending, inhalable sildenafil, marketed as VigorAir ™ . (While sildenafil and eletriptan have … |
| GLD-MANAGEMENT-INC | GLD-MANAGEMENT-INC | 62% | faces strong competition in the on-line prescription fulfillment marketplace, particularly for GLP-1 agonist weight loss drugs and erectile dysfunction formulations as industry leaders Hims/Hers and … |
| LEVITY-HEALTHCARE-INC | LEVITY-HEALTHCARE-INC | 62% | faces strong competition in the on-line prescription fulfillment marketplace, particularly for GLP-1 agonist weight loss drugs and erectile dysfunction formulations as industry leaders Hims/Hers and … |
| PINATA-HOLDINGS-INC | PINATA-HOLDINGS-INC | 62% | ce, and to amend its description of goods. The Company has received an extension to respond to the USPTO letter until October 24, 2025. On October 24, the Company filed a response with the USPTO amen… |
| REPRISE-MANAGEMENT-INC | REPRISE-MANAGEMENT-INC | 62% | ceived by Business Entities. This AS U amends ASC 832 to include guidance on the recognition, measurement, and presentation of government grants, leveraging the principles in IAS 20. Given the simila… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| PMHS-DEBT-11821 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| PMHS-DEBT | Debt stack $33,849 | 90% | Market cache reports total debt of $33,849. |